Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

New data presented in two separate oral presentations at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC...

Related Keywords

Italy ,United States ,Italian ,Douglas Mayers ,Istituto Nazionale Genetica Molecolare ,Luca Guidotti ,World Health Organization ,Antios Therapeutics Inc ,European Association ,International Liver Congress ,Antios Therapeutics ,Active Site Polymerase Inhibitor Nucleotide ,Chief Medical Officer ,Deputy Scientific Director ,San Raffaele Hospital ,Scientific Advisor ,Antios Therapeutic ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,